NASDAQ:KALA Kala Pharmaceuticals (KALA) Stock Forecast, Price & News $15.05 +0.29 (+1.96%) (As of 05/26/2023 03:59 PM ET) Add Compare Share Share Today's Range$15.00▼$15.8650-Day Range$13.71▼$18.6352-Week Range$3.54▼$56.72Volume38,700 shsAverage Volume824,992 shsMarket Capitalization$35.35 millionP/E RatioN/ADividend YieldN/APrice Target$35.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Kala Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside135.9% Upside$35.50 Price TargetShort InterestBearish9.38% of Float Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($18.79) to ($10.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector452nd out of 1,010 stocksPharmaceutical Preparations Industry210th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingKala Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.50, Kala Pharmaceuticals has a forecasted upside of 135.9% from its current price of $15.05.Amount of Analyst CoverageKala Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.38% of the float of Kala Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKala Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kala Pharmaceuticals has recently increased by 12.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKala Pharmaceuticals does not currently pay a dividend.Dividend GrowthKala Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKala Pharmaceuticals has received a 66.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Glucocorticoids" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kala Pharmaceuticals is -1.35. Previous Next 2.7 News and Social Media Coverage News SentimentKala Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kala Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest8 people have searched for KALA on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Kala Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kala Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.40% of the stock of Kala Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kala Pharmaceuticals are expected to grow in the coming year, from ($18.79) to ($10.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kala Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kala Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKala Pharmaceuticals has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kala Pharmaceuticals (NASDAQ:KALA) StockKala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.Read More Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Stock News HeadlinesMay 26, 2023 | fool.comKala Pharmaceuticals (NASDAQ: KALA)May 19, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Bausch + Lomb Corporation (BLCO)May 29, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,May 18, 2023 | markets.businessinsider.comAslan Pharmaceuticals (ASLN) Receives a Buy from H.C. WainwrightMay 11, 2023 | finance.yahoo.com10 Best Stocks to Buy for a Quick ReturnMay 11, 2023 | markets.businessinsider.comKala Pharmaceuticals (KALA) Gets a Buy from WedbushMay 10, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Kala Pharmaceuticals (KALA)May 10, 2023 | americanbankingnews.comKala Pharmaceuticals (NASDAQ:KALA) Price Target Increased to $24.00 by Analysts at HC WainwrightMay 29, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,May 9, 2023 | finance.yahoo.comKala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 5, 2023 | marketwatch.comThyroid Eye Treatment Market 2023-2031| Discover Industry Scope and OpportunitiesMay 1, 2023 | msn.comHC Wainwright & Co. Reiterates Kala Pharmaceuticals (KALA) Buy RecommendationMay 1, 2023 | markets.businessinsider.comWhere Kala Pharmaceuticals Stands With AnalystsMay 1, 2023 | markets.businessinsider.comKala Pharmaceuticals (KALA) Gets a Buy from H.C. WainwrightApril 28, 2023 | marketwatch.com8-K: Kala Pharmaceuticals, Inc.April 28, 2023 | markets.businessinsider.comKala Pharmaceuticals Adds 6% In Morning TradeApril 28, 2023 | finance.yahoo.comCombangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCEDApril 19, 2023 | msn.comMadrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy TagApril 14, 2023 | americanbankingnews.comKala Pharmaceuticals (NASDAQ:KALA) PT Raised to $22.00 at HC WainwrightApril 13, 2023 | msn.comHC Wainwright & Co. Maintains Kala Pharmaceuticals (KALA) Buy RecommendationApril 13, 2023 | msn.comKALA Up on Fast Track Designation to Lead Ocular CandidateApril 12, 2023 | markets.businessinsider.comKala Pharmaceuticals Ascends 5% On Getting Fast Track Designation For Its KPI-012April 12, 2023 | finance.yahoo.comKala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial DefectApril 6, 2023 | finance.yahoo.comKala Pharmaceuticals (KALA) Dips More Than Broader Markets: What You Should KnowMarch 30, 2023 | finance.yahoo.comKala Pharmaceuticals (KALA) Stock Sinks As Market Gains: What You Should KnowMarch 29, 2023 | finance.yahoo.comKala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical AdvisorMarch 29, 2023 | americanbankingnews.comKala Pharmaceuticals (NASDAQ:KALA) Given "Buy" Rating at HC WainwrightSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Company Calendar Last Earnings5/09/2023Today5/29/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALA CUSIPN/A CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees192Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.50 High Stock Price Forecast$47.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+135.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($14.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,820,000.00 Net Margins-1,383.91% Pretax Margin-1,045.08% Return on Equity-1,062.69% Return on Assets-31.95% Debt Debt-to-Equity Ratio1.64 Current Ratio6.95 Quick Ratio6.95 Sales & Book Value Annual Sales$2.52 million Price / Sales14.03 Cash FlowN/A Price / Cash FlowN/A Book Value$11.12 per share Price / Book1.35Miscellaneous Outstanding Shares2,349,000Free Float2,034,000Market Cap$35.35 million OptionableOptionable Beta-1.56 Key ExecutivesMark T. IwickiChairman & Chief Executive OfficerTodd BazemorePresident & Chief Operating OfficerMary E. ReumuthChief Financial OfficerRomulus Kim BrazzellChief Medical Officer, Head-Research & DevelopmentEric L. TrachtenbergSecretary & Chief Compliance OfficerKey CompetitorsAvalo TherapeuticsNASDAQ:AVTXMagenta TherapeuticsNASDAQ:MGTAVincerx PharmaNASDAQ:VINCSynlogicNASDAQ:SYBXMustang BioNASDAQ:MBIOView All CompetitorsInsiders & InstitutionsJane Street Group LLCSold 13,581 shares on 5/16/2023Ownership: 0.527%Susquehanna International Group LLPSold 53,100 shares on 5/16/2023Ownership: 0.000%BlackRock Inc.Bought 5,675 shares on 5/12/2023Ownership: 1.053%Bank of America Corp DESold 7,934 shares on 5/12/2023Ownership: 0.264%UBS Group AGBought 1,608 shares on 5/12/2023Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions KALA Stock - Frequently Asked Questions Should I buy or sell Kala Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KALA shares. View KALA analyst ratings or view top-rated stocks. What is Kala Pharmaceuticals' stock price forecast for 2023? 1 analysts have issued twelve-month price objectives for Kala Pharmaceuticals' shares. Their KALA share price forecasts range from $24.00 to $47.00. On average, they predict the company's share price to reach $35.50 in the next year. This suggests a possible upside of 135.9% from the stock's current price. View analysts price targets for KALA or view top-rated stocks among Wall Street analysts. How have KALA shares performed in 2023? Kala Pharmaceuticals' stock was trading at $38.15 on January 1st, 2023. Since then, KALA shares have decreased by 60.6% and is now trading at $15.05. View the best growth stocks for 2023 here. When is Kala Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our KALA earnings forecast. How were Kala Pharmaceuticals' earnings last quarter? Kala Pharmaceuticals, Inc. (NASDAQ:KALA) issued its earnings results on Tuesday, May, 9th. The company reported ($6.99) EPS for the quarter, missing analysts' consensus estimates of ($5.10) by $1.89. Kala Pharmaceuticals had a negative trailing twelve-month return on equity of 1,062.69% and a negative net margin of 1,383.91%. When did Kala Pharmaceuticals' stock split? Shares of Kala Pharmaceuticals reverse split on the morning of Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO? 1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Kala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV). When did Kala Pharmaceuticals IPO? (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. What is Kala Pharmaceuticals' stock symbol? Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA." Who are Kala Pharmaceuticals' major shareholders? Kala Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%), BlackRock Inc. (1.05%), Jane Street Group LLC (0.53%), Bank of America Corp DE (0.26%), UBS Group AG (0.09%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Eric Trachtenberg, Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Ra Capital Management, LP, Romulus K Brazzell and Todd Bazemore. View institutional ownership trends. How do I buy shares of Kala Pharmaceuticals? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kala Pharmaceuticals' stock price today? One share of KALA stock can currently be purchased for approximately $15.05. How much money does Kala Pharmaceuticals make? Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $35.35 million and generates $2.52 million in revenue each year. The company earns $-44,820,000.00 in net income (profit) each year or ($14.71) on an earnings per share basis. How many employees does Kala Pharmaceuticals have? The company employs 192 workers across the globe. How can I contact Kala Pharmaceuticals? Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399. This page (NASDAQ:KALA) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.